A Study of LY3462817 in Participants With Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2022-07-15
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3462817 is safe and effective in
participants with moderately to severely active rheumatoid arthritis (RA).